Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer

NCT03690739 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT03690739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03690739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer
Lead sponsor
AGO Research GmbH
Phase
Phase 3
Overall status
Terminated
Start date
August 9, 2019
Completion date
March 3, 2021
Enrollment
9 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ovarian carcinoma